| American Federation for Aging Research | |
|---|---|
| Logo placeholder | |
| Location | New York, NY, USA |
| Type | Non-profit Research Foundation |
| Founded | 1969 |
| Website | https://www.afar.org/ |
| Focus Areas | Aging Biology, Alzheimer's Disease, Parkinson's Disease, Age-Related Diseases |
| Partner | Glenn Foundation for Medical Research |
The American Federation for Aging Research (AFAR) is a leading non-profit organization dedicated to supporting cutting-edge research on the biology of aging and age-related diseases. Founded in 1969, AFAR has become one of the premier funders of aging research in the United States, providing grants and fellowships to emerging and established scientists studying the mechanisms of aging and its relationship to neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease[1].
AFAR's mission is to advance understanding of the biological processes that underlie aging and age-related diseases, with the ultimate goal of developing interventions that can extend healthy lifespan and prevent or treat age-related neurodegenerative conditions. The organization achieves this through its grant programs, public education initiatives, and strategic partnerships with other research foundations[2].
AFAR was founded in 1969 by a group of physicians and scientists who recognized the growing importance of aging research as life expectancy increased in the United States. From its inception, AFAR has focused on supporting innovative research that explores the fundamental biology of aging and its implications for human health[1:1].
The organization was established during a period of increasing awareness about the challenges posed by an aging population. As medical advances led to longer lifespans, the incidence of age-related diseases including Alzheimer's and Parkinson's also rose, creating an urgent need for research into the underlying mechanisms of aging itself[2:1].
Over the past five decades, AFAR has evolved from a small professional organization into a major force in aging research. The federation has supported thousands of researchers and has played a pivotal role in establishing aging research as a legitimate and important field of scientific inquiry. AFAR has been instrumental in fostering the careers of many leading researchers in the field of gerontology and neurodegenerative disease research[3].
AFAR administers several major grant programs that support research on the biology of aging:
AFAR Research Grants provide funding to established investigators pursuing innovative research projects focused on the basic biology of aging. These grants are designed to support projects that may be too innovative or high-risk for traditional funding mechanisms but have the potential to significantly advance the field[1:2].
AFAR Junior Faculty Awards support early-career investigators who are establishing independent research programs in aging research. These awards are particularly important for researchers seeking to make the transition from postdoctoral training to independent faculty positions[2:2].
AFAR postdoctoral Fellowships provide support for promising young researchers who are training in laboratories focused on aging-related research. These fellowships are designed to cultivate the next generation of leaders in the field[3:1].
AFAR maintains a significant partnership with the Glenn Foundation for Medical Research (GFMR), which has enabled the organization to expand its funding portfolio significantly. This partnership supports the Glenn Foundation's mission to advance understanding of the biological mechanisms of aging through supporting high-quality research programs[4].
The AFAR-GFMR partnership has funded numerous studies on the cellular and molecular mechanisms of aging, including research on:
AFAR has been a significant supporter of Alzheimer's Disease research, funding studies that explore the intersection of aging biology and Alzheimer's pathogenesis. Research funded by AFAR has contributed to understanding how aging-related cellular processes may contribute to amyloid-beta accumulation, tau phosphorylation, and neurodegeneration in Alzheimer's disease[1:3][2:3].
Key areas of AFAR-funded Alzheimer's research include:
Similarly, AFAR supports Parkinson's Disease research that examines how aging-related mechanisms contribute to dopaminergic neuron loss and Parkinson's pathogenesis. The organization has funded research on:
AFAR recognizes outstanding contributions to aging research through its awards programs:
The Irving S. Zuckerman Award is AFAR's highest honor, awarded to researchers who have made exceptional contributions to the field of aging biology[2:4].
AFAR Grantee Highlights showcase recent discoveries by AFAR-funded researchers, including advances in understanding:
AFAR's current strategic priorities include:
Expanding Funding for Neurodegeneration Research - Increasing support for research that examines the relationship between aging biology and neurodegenerative diseases[1:4]
Training the Next Generation - Continuing to invest in early-career researchers through fellowships and junior faculty awards[2:5]
Promoting Translation - Supporting research that has potential for clinical application in treating or preventing age-related diseases[3:4]
Public Education - Disseminating evidence-based information about aging and age-related diseases to healthcare professionals and the public[4:1]
AFAR has been instrumental in supporting research that has defined the hallmarks of aging framework, originally published in Cell in 2013[5] and expanded in 2023[6]. This conceptual framework identifies the fundamental cellular and molecular processes that contribute to aging and age-related diseases:
| Hallmark | Relevance to Neurodegeneration |
|---|---|
| Genomic instability | Accumulation of DNA damage in neurons |
| Telomere attrition | Neural stem cell exhaustion |
| Epigenetic alterations | Dysregulated gene expression in aging brains |
| Loss of proteostasis | Protein aggregation in AD and PD |
| Deregulated nutrient sensing | Metabolic dysfunction in neurodegeneration |
| Mitochondrial dysfunction | Energy failure in dopaminergic neurons |
| Cellular senescence | Senescent glia contribute to neuroinflammation |
| Stem cell exhaustion | Impaired neural regeneration |
| Altered intercellular communication | Dysregulated neuroimmune signaling |
AFAR has supported pioneering research on senolytics - drugs that selectively eliminate senescent cells - which has emerged as a promising therapeutic approach for age-related neurodegenerative diseases[7]:
AFAR-funded research has demonstrated that clearing senescent cells can:
Research funded by AFAR has advanced understanding of mitochondrial dysfunction in aging neurons and explored interventions:
AFAR has supported research on the critical role of neuroinflammation in neurodegeneration:
AFAR Research Grants provide $100,000-$150,000 over 1-2 years for established investigators. Priority areas include:
The AFAR Junior Faculty Award in Aging provides $80,000 over two years for early-career investigators. Recent recipients have conducted research on:
Through the partnership with GFMR, AFAR distributes:
AFAR administers the prestigious Paul Beeson Aging Research Fellowship, a $500,000 award over three years for early-career physician-scientists focused on aging-related research.
| Metric | Value |
|---|---|
| Active grantees annually | 150+ |
| Cumulative grants awarded | 2,500+ |
| Papers published by grantees | 10,000+ |
| Grantees in NIH-funded positions | 75%+ |
AFAR has played a critical role in developing the next generation of aging researchers:
AFAR-funded research has contributed to major advances including:
AFAR works closely with the National Institute on Aging (NIA) and other NIH institutes:
AFAR supports international research through:
AFAR facilitates translation through industry collaborations:
AFAR's strategic plan for 2025-2030 focuses on:
AFAR is expanding its programs in several areas:
AFAR is embracing new technologies: